Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases.
Adv Rheumatol
; 60(1): 32, 2020 06 09.
Article
en En
| MEDLINE
| ID: mdl-32517786
ABSTRACT
Hydroxychloroquine and chloroquine, also known as antimalarial drugs, are widely used in the treatment of rheumatic diseases and have recently become the focus of attention because of the ongoing COVID-19 pandemic. Rheumatologists have been using antimalarials to manage patients with chronic immune-mediated inflammatory rheumatic diseases for decades. It is an appropriate time to review their immunomodulatory and anti-inflammatory mechanisms impact on disease activity and survival of systemic lupus erythematosus patient, including antiplatelet effect, metabolic and lipid benefits. We also discuss possible adverse effects, adding a practical and comprehensive approach to monitoring rheumatic patients during treatment with these drugs.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Artritis Reumatoide
/
Cloroquina
/
Hidroxicloroquina
/
Lupus Eritematoso Sistémico
/
Antimaláricos
Tipo de estudio:
Etiology_studies
/
Systematic_reviews
Límite:
Female
/
Humans
/
Male
/
Pregnancy
Idioma:
En
Revista:
Adv Rheumatol
Año:
2020
Tipo del documento:
Article
País de afiliación:
Brasil